Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11899303 | 1.00 | USP2 (0.51) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL2398170 | 1.00 | USP2 (0.51) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL2398277 | 1.00 | USP2 (0.51) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL2398172 | 1.00 | USP2 (0.51) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL14339072 | 0.96 | USP2 (0.56) | USP2HTTP2RY10LPAR1LPAR3 | |
| SCHEMBL12943223 | 0.92 | ALDH1A1 (0.56) | USP2ALDH1A1CNR1CNR2LPAR1 | |
| SCHEMBL14848905 | 0.90 | USP2 (0.59) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL14841798 | 0.90 | USP2 (0.59) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL4814012 | 0.90 | USP2 (0.59) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL14848735 | 0.90 | USP2 (0.59) | USP2HTTALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224447-A1 | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224447-A1 | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| WO-2010080724-A1 | NOVEL LIPID NANOPARTICLES AND NOVEL COMPONENTS FOR DELIVERY OF NUCLEIC ACIDS | MERCK SHARP & DOHME CORP. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010021865-A1 | NOVEL LIPID NANOPARTICLES AND NOVEL COMPONENTS FOR DELIVERY OF NUCLEIC ACIDS | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224447-A1 | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids | NPC1, ABHD16A, NPC1L1 | USP2 2809/4885HTT 2635/4885ALDH1A1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.